Rani Therapeutics Holdings Inc Cl A (RANI) Stock Price, Quote & News

Company Profile

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes...

Industry: Biotechnology

Sector: Healthcare

Phone: 408 457 3700

Website: www.ranitherapeutics.com

Address:

2051 Ringwood Avenue, San Jose, United States

llchen1204 Mar. 15 at 4:57 PM

$RANI

0 · Reply

JaJadingdong1 Mar. 14 at 3:37 PM

$RANI Pop coming sooner rather than later.

0 · Reply

DragonAlgo Mar. 13 at 12:49 PM

🐉 $RANI PUT — DragonAlgo® Signal Contract: RANI PUT Expiry: 2026-03-13 | Strike: $1.00 | Type: PUT Option Plan (premium): Entry: $0.02 Stop: $0.01 TP1: $0.03 TP2: $0.03 TP3: $0.05 🔗 https://dragonalgo.com

0 · Reply

Hakapeszi Mar. 12 at 4:56 PM

$RANI volume is OK, added more.

0 · Reply

DragonAlgo Mar. 12 at 5:53 AM

🐉 $RANI CALL — DragonAlgo® Signal Contract: RANI CALL Expiry: 2026-03-27 | Strike: $1.50 | Type: CALL Option Plan (premium): Entry: $0.08 Stop: $0.06 TP1: $0.10 TP2: $0.14 TP3: $0.19 Rules-based execution profile. 🔗 https://dragonalgo.com

0 · Reply

wavw Mar. 11 at 2:17 PM

$RANI when is the last day for filing.

0 · Reply

DragonAlgo Mar. 11 at 1:26 PM

🐉 $RANI CALL — DragonAlgo® Signal Contract: RANI CALL Expiry: 2026-03-27 | Strike: $1.50 | Type: CALL Option Plan (premium): Entry: $0.08 Stop: $0.06 TP1: $0.10 TP2: $0.14 TP3: $0.19 Active momentum environment. 🔗 https://dragonalgo.com

0 · Reply

wavw Mar. 10 at 1:54 PM

$RANI someone holding this level around 1.38-1.40. Not allowing to break..

2 · Reply

BBTAAPL Mar. 10 at 12:13 PM

$RANI let’s run!

2 · Reply

JaJadingdong1 Mar. 9 at 7:53 PM

$RANI look

0 · Reply

Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer

Jan 8, 2026, 7:00 AM EST - 2 months ago

Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen

Nov 24, 2025, 4:05 PM EST - 3 months ago

Rani Therapeutics to Participate in the Evercore Healthcare Conference

Nov 6, 2025, 4:30 PM EST - 4 months ago

Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update

Oct 30, 2025, 8:00 AM EDT - 4 months ago

Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025

Oct 23, 2025, 4:05 PM EDT - 5 months ago

Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors

Oct 23, 2025, 4:01 PM EDT - 5 months ago

Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules

Oct 20, 2025, 2:20 PM EDT - 5 months ago

Rani Therapeutics: Initiating At Buy On Promising RaniPill Advancement With Chugai

Oct 20, 2025, 9:42 AM EDT - 5 months ago

CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why

CELC CRMD RAPT

Oct 17, 2025, 7:48 AM EDT - 5 months ago

Rani Therapeutics signs up to $1.09 billion licensing deal with Japan's Chugai Pharma

Oct 17, 2025, 7:31 AM EDT - 5 months ago

Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules

Oct 17, 2025, 7:30 AM EDT - 5 months ago

Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing

Aug 7, 2025, 4:05 PM EDT - 7 months ago

Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update

Jul 15, 2025, 9:00 AM EDT - 8 months ago

Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering

Jul 14, 2025, 5:00 AM EDT - 8 months ago

Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery

May 19, 2025, 8:00 AM EDT - 10 months ago

Rani Therapeutics Announces Research Agreement with Chugai

May 13, 2025, 4:05 PM EDT - 10 months ago

Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update

Mar 31, 2025, 7:15 PM EDT - 1 year ago

Rani Therapeutics Holdings, Inc. (RANI) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 4:05 PM EDT - 1 year ago

Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update

Mar 26, 2025, 4:05 PM EDT - 1 year ago

Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102

Mar 25, 2025, 6:00 PM EDT - 1 year ago

Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Oct 15, 2024, 8:30 AM EDT - 1 year ago

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing Warrants

Oct 8, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit

Sep 3, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics to Participate in September Investor Conferences

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update

Jul 29, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics to Participate in August Investor Conferences

Jul 22, 2024, 8:30 AM EDT - 1 year ago

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment

May 14, 2024, 8:00 AM EDT - 1 year ago

Rani Therapeutics to Participate in May Investor Conferences

May 9, 2024, 8:00 AM EDT - 2 years ago

Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024

May 6, 2024, 4:05 PM EDT - 2 years ago

Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update

Mar 20, 2024, 7:05 PM EDT - 2 years ago

Rani Therapeutics Holdings, Inc. (RANI) Q4 2023 Earnings Call Transcript

Mar 20, 2024, 4:05 PM EDT - 2 years ago

Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update

Mar 15, 2024, 4:05 PM EDT - 2 years ago

Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

Dec 14, 2023, 8:00 AM EST - 2 years ago

Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist

Nov 8, 2023, 4:05 PM EST - 2 years ago

Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update

Oct 19, 2023, 4:05 PM EDT - 2 years ago

Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study

Oct 12, 2023, 4:05 PM EDT - 2 years ago

Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research

Sep 19, 2023, 6:36 AM EDT - 2 years ago

Rani Therapeutics: Excellent Technology But Major Risks Ahead

Sep 18, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)

Sep 7, 2023, 4:05 PM EDT - 2 years ago

Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies

Aug 11, 2023, 4:05 PM EDT - 2 years ago

Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update

Jun 21, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics' Presentation On Oral Delivery of PTH for Osteoporosis Named Presidential Poster Competition Winner at ENDO 2023 Annual Conference

Jun 8, 2023, 8:00 AM EDT - 3 years ago

Rani Therapeutics Announces Acceptance of Late-Breaking Abstract of Oral Delivery of GLP-1 Agonist at the American Diabetes Association Annual Conference

Jun 5, 2023, 8:00 AM EDT - 3 years ago

Rani Therapeutics and Celltrion Expand Partnership to Include Adalimumab Biosimilar for RT-105

Jun 1, 2023, 8:00 AM EDT - 3 years ago

Rani Therapeutics to Present at the Jefferies Healthcare Conference

May 31, 2023, 8:00 AM EDT - 3 years ago

Rani Therapeutics Announces Acceptance of Three Abstracts for Presentation at ENDO 2023 Annual Conference

May 24, 2023, 8:00 AM EDT - 3 years ago

Rani Therapeutics Appoints Kate McKinley as Chief Business Officer

May 10, 2023, 4:05 PM EDT - 3 years ago

Rani Therapeutics Reports First Quarter 2023 Financial Results; Provides Corporate Update

llchen1204 Mar. 15 at 4:57 PM

$RANI

0 · Reply

JaJadingdong1 Mar. 14 at 3:37 PM

$RANI Pop coming sooner rather than later.

0 · Reply

DragonAlgo Mar. 13 at 12:49 PM

0 · Reply

Hakapeszi Mar. 12 at 4:56 PM

$RANI volume is OK, added more.

0 · Reply

DragonAlgo Mar. 12 at 5:53 AM

0 · Reply

wavw Mar. 11 at 2:17 PM

$RANI when is the last day for filing.

0 · Reply

DragonAlgo Mar. 11 at 1:26 PM

🐉 $RANI CALL — DragonAlgo® Signal Contract: RANI CALL Expiry: 2026-03-27 | Strike: $1.50 | Type: CALL Option Plan (premium): Entry: $0.08 Stop: $0.06 TP1: $0.10 TP2: $0.14 TP3: $0.19 Active momentum environment. 🔗 https://dragonalgo.com

0 · Reply

wavw Mar. 10 at 1:54 PM

$RANI someone holding this level around 1.38-1.40. Not allowing to break..

2 · Reply

BBTAAPL Mar. 10 at 12:13 PM

$RANI let’s run!

2 · Reply

JaJadingdong1 Mar. 9 at 7:53 PM

$RANI look

0 · Reply

wavw Mar. 9 at 7:01 PM

$RANI my estimation is 5 million every month for each drug from Chugai. Normally clients release partial payments as they progress.

0 · Reply

APRadek Mar. 9 at 4:55 PM

$RANI is there going to be something bullish in upcoming earnings? Upfront payment from chugai? What else? Corporate update?

0 · Reply

wavw Mar. 8 at 11:47 PM

$RANI not the right time…whole market is crashing

1 · Reply

JaJadingdong1 Mar. 8 at 6:58 PM

$RANI Come on results

0 · Reply

BBTAAPL Mar. 5 at 8:34 PM

$RANI you can tell this is coiled & ready to blow. I think we will see huge movement in the next couple of weeks. Now is the time to accumulate

0 · Reply

wavw Mar. 5 at 8:20 PM

$RANI someone collecting shares happily.

1 · Reply

DragonAlgo Mar. 5 at 7:55 AM

🐉 $RANI CALL — DragonAlgo® Signal Contract: RANI CALL Expiry: 2026-03-06 | Strike: $0.50 | Type: CALL Option Plan (premium): Entry: $0.77 Stop: $0.55 TP1: $1.00 TP2: $1.31 TP3: $1.85 🔗 https://dragonalgo.com

0 · Reply

wavw Mar. 4 at 9:43 PM

$RANI last time I remember seeing 28% tutes holding. Now 50.06%. This will be above 10 soon

0 · Reply

BBTAAPL Mar. 4 at 6:51 PM

$RANI let’s run this shit!

0 · Reply

Fishbonee Mar. 4 at 2:54 PM

$RANI

0 · Reply

Hakapeszi Mar. 4 at 1:10 PM

$RANI news of ProGen PG-102 phase2a https://www.koreabiomed.com/news/articleView.html?idxno=30781

0 · Reply

DragonAlgo Mar. 4 at 10:33 AM

0 · Reply

Market Cap	160.40M
Revenue (ttm)	1.03M
Net Income (ttm)	-30.02M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,914.56%
Debt to Equity Ratio	-1.88

Volume	790,300
Avg Vol	1,013,582
Day's Range	N/A - N/A
Shares Out	121.51M
Stochastic %K	40%
Beta	0.39
Analysts	Strong Sell
Price Target	$8.00